{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:09:35Z","timestamp":1793812175777,"version":"4.6.1"},"reference-count":257,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Human cytomegalovirus (HCMV) is one of the main causes of serious complications in immunocompromised patients and after congenital infection. There are currently drugs available to treat HCMV infection, targeting viral polymerase, whose use is complicated by toxicity and the emergence of resistance. Maribavir and letermovir are the latest antivirals to have been developed with other targets. The approval of letermovir represents an important innovation for CMV prevention in hematopoietic stem cell transplant recipients, whereas maribavir allowed improving the management of refractory or resistant infections in transplant recipients. However, in case of multidrug resistance or for the prevention and treatment of congenital CMV infection, finding new antivirals or molecules able to inhibit CMV replication with the lowest toxicity remains a critical need. This review presents a range of molecules known to be effective against HCMV. Molecules with a direct action against HCMV include brincidofovir, cyclopropavir and anti-terminase benzimidazole analogs. Artemisinin derivatives, quercetin and baicalein, and anti-cyclooxygenase-2 are derived from natural molecules and are generally used for different indications. Although they have demonstrated indirect anti-CMV activity, few clinical studies were performed with these compounds. Immunomodulating molecules such as leflunomide and everolimus have also demonstrated indirect antiviral activity against HCMV and could be an interesting complement to antiviral therapy. The efficacy of anti-CMV immunoglobulins are discussed in CMV congenital infection and in association with direct antiviral therapy in heart transplanted patients. All molecules are described, with their mode of action against HCMV, preclinical tests, clinical studies and possible resistance. All these molecules have shown anti-HCMV potential as monotherapy or in combination with others. These new approaches could be interesting to validate in clinical trials.<\/jats:p>","DOI":"10.3389\/fmicb.2023.1321116","type":"journal-article","created":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T23:25:03Z","timestamp":1700436303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Anti-CMV therapy, what next? A systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Claire","family":"Gourin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Alain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Hantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(03)15162-8","article-title":"Artesunate combinations for treatment of malaria: meta-analysis","volume":"363","author":"Adjuik","year":"2004","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1089\/vim.2016.0151","article-title":"Interaction of immunoglobulin with cytomegalovirus-infected cells","volume":"30","author":"Aiba","year":"2017","journal-title":"Viral Immunol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/jac\/dkaa135","article-title":"Letermovir breakthroughs during the French named patient Programme: interest of monitoring blood concentration in clinical practice","volume":"75","author":"Alain","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1124\/mol.63.3.678","article-title":"Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism","volume":"63","author":"Aldern","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41409-018-0166-9","article-title":"Cytotect\u00aeCP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study","volume":"53","author":"Alsuliman","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/fmb-2019-0288","article-title":"Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections","volume":"15","author":"Alvarez-Cardona","year":"2020","journal-title":"Future Microbiol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1021\/np50090a003","article-title":"Synergistic effect of flavones and flavonols against herpes simplex virus type 1 in cell culture. Comparison with the antiviral activity of propolis","volume":"55","author":"Amoros","year":"1992","journal-title":"J. Nat. Prod."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/13596535211064078","article-title":"Impact of new cyclooxygenase 2 inhibitors on human cytomegalovirus replication in vitro","volume":"26","author":"Andouard","year":"2021","journal-title":"Antivir. Ther."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.antiviral.2016.02.004","article-title":"Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: benefits and limits of 3D analysis","volume":"129","author":"Andouard","year":"2016","journal-title":"Antivir. Res."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e10370","DOI":"10.1371\/journal.pone.0010370","article-title":"Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers","volume":"5","author":"Arav-Boger","year":"2010","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e13166","DOI":"10.1111\/tid.13166","article-title":"Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients","volume":"21","author":"Aryal","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jviromet.2011.03.005","article-title":"A reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad anti-herpesviral drug artesunate","volume":"173","author":"Auerochs","year":"2011","journal-title":"J. Virol. Methods"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/TP.0b013e3181e94106","article-title":"Utility of Leflunomide in the treatment of complex cytomegalovirus syndromes","volume":"90","author":"Avery","year":"2010","journal-title":"Transplantation"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1172\/JCI57147","article-title":"Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target","volume":"121","author":"Baryawno","year":"2011","journal-title":"J. Clin. Invest."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of Cidofovir and cyclic Cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"105106","DOI":"10.1016\/j.jcv.2022.105106","article-title":"Effective Letermovir prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: results from the French temporary authorization of use compassionate program","volume":"148","author":"Beauvais","year":"2022","journal-title":"J. Clin. Virol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3248S","DOI":"10.1093\/jn\/133.10.3248S","article-title":"Overview of dietary flavonoids: nomenclature, occurrence and intake","volume":"133","author":"Beecher","year":"2003","journal-title":"J. Nutr."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/infdis\/142.5.732","article-title":"Vaccination for the prevention of maternal and fetal infection with Guinea pig cytomegalovirus","volume":"142","author":"Bia","year":"1980","journal-title":"J. Infect. Dis."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1086\/421912","article-title":"Oral activity of ether lipid Ester prodrugs of Cidofovir against experimental human cytomegalovirus infection","volume":"190","author":"Bidanset","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a Benzimidazole l-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.bbrc.2005.10.031","article-title":"The reversibility of the glutathionyl-quercetin adduct spreads oxidized quercetin-induced toxicity","volume":"338","author":"Boots","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/infdis\/172.4.944","article-title":"Effect of passive antibody on congenital cytomegalovirus infection in Guinea pigs","volume":"172","author":"Bratcher","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1128\/AAC.00971-10","article-title":"Oral Hexadecyloxypropyl-Cidofovir therapy in pregnant Guinea pigs improves outcome in the congenital model of cytomegalovirus infection","volume":"55","author":"Bravo","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between Everolimus versus mycophenolate in De novo renal transplants: pooled analysis of three clinical trials","volume":"11","author":"Brennan","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref26","author":"Brooks","year":"2013"},{"key":"ref27","author":"Brooks","year":"2015"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"9077","DOI":"10.1128\/JVI.75.19.9077-9086.2001","article-title":"A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products","volume":"75","author":"Buerger","year":"2001","journal-title":"J. Virol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1515\/jpm-2011-0257","article-title":"Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis","volume":"40","author":"Buxmann","year":"2012","journal-title":"J. Perinat. Med."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000001095","article-title":"The immunology of Posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV","volume":"100","author":"Carbone","year":"2016","journal-title":"Transplantation"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2174\/138955708786369564","article-title":"Flavonoids: prospective drug candidates","volume":"8","author":"Cazarolli","year":"2008","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"12172","DOI":"10.1128\/JVI.01214-08","article-title":"Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice","volume":"82","author":"Cekinovi\u0107","year":"2008","journal-title":"J. Virol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.bcp.2010.06.050","article-title":"Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy","volume":"80","author":"Cerella","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2174\/092986710790979980","article-title":"Progress in COX-2 inhibitors: a journey so far","volume":"17","author":"Chakraborti","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1142\/S0192415X1650052X","article-title":"Baicalein, a constituent of Scutellaria baicalensis, reduces glutamate release and protects neuronal cell against Kainic acid-induced excitotoxicity in rats","volume":"44","author":"Chang","year":"2016","journal-title":"Am. J. Chin. Med."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1086\/320714","article-title":"Modification of maternal and congenital cytomegalovirus infection by anti\u2013glycoprotein B antibody transfer in Guinea pigs","volume":"183","author":"Chatterjee","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ajog.2020.05.038","article-title":"Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences","volume":"223","author":"Chatzakis","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/AAC.00449-16","article-title":"Potency and Stereoselectivity of Cyclopropavir triphosphate action on human cytomegalovirus DNA polymerase","volume":"60","author":"Chen","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00404-018-4703-y","article-title":"No evidence of obstetrical adverse events after hyperimmune globulin application for primary cytomegalovirus infection in pregnancy: experience from a single Centre","volume":"297","author":"Chiaie","year":"2018","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref42","year":"2022"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-6143.2005.01152.x","article-title":"Concurrent antiviral and immunosuppressive activities of Leflunomide in vivo","volume":"6","author":"Chong","year":"2006","journal-title":"Am. J. Transplant."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1128\/AAC.01177-08","article-title":"Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under Maribavir","volume":"53","author":"Chou","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e01325","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of cytomegalovirus Terminase gene mutations selected after exposure to three distinct inhibitor compounds","volume":"61","author":"Chou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antivir. Res."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"jiad293","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of Maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","author":"Chou","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/AAC.01259-10","article-title":"Cytomegalovirus UL97 mutations affecting Cyclopropavir and ganciclovir susceptibility","volume":"55","author":"Chou","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1128\/AAC.00214-16","article-title":"Novel cytomegalovirus UL54 DNA polymerase gene mutations selected in vitro that confer Brincidofovir resistance","volume":"60","author":"Chou","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1128\/AAC.00511-13","article-title":"Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance","volume":"57","author":"Chou","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"","journal-title":"Antivir. Res."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1128\/JVI.01787-07","article-title":"Accelerated evolution of Maribavir resistance in a cytomegalovirus exonuclease domain II mutant","volume":"82","author":"Chou","year":"2008","journal-title":"J. Virol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.antiviral.2011.07.018","article-title":"The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants","volume":"92","author":"Chou","year":"2011","journal-title":"Antivir. Res."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1128\/AAC.05559-11","article-title":"Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure","volume":"56","author":"Chou","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1128\/JVI.78.13.7124-7130.2004","article-title":"Mutations in the human cytomegalovirus UL27 gene that confer resistance to Maribavir","volume":"78","author":"Chou","year":"2004","journal-title":"J. Virol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1086\/518514","article-title":"Cytomegalovirus UL97 kinase mutations that confer Maribavir resistance","volume":"196","author":"Chou","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"104616","DOI":"10.1016\/j.antiviral.2019.104616","article-title":"Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","volume":"172","author":"Chou","year":"2019","journal-title":"Antivir. Res."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"105661","DOI":"10.1016\/j.antiviral.2023.105661","article-title":"New therapeutic perspective in the prevention of congenital cytomegalovirus infection","volume":"216","author":"Coste Mazeau","year":"2023","journal-title":"Antivir. Res."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/microorganisms10040694","article-title":"Potential of anti-CMV immunoglobulin Cytotect CP\u00ae in vitro and ex vivo in a first-trimester placenta model","volume":"10","author":"Coste Mazeau","year":"2022","journal-title":"Microorganisms"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.antiviral.2012.09.010","article-title":"Eight flavonoids and their potential as inhibitors of human cytomegalovirus replication","volume":"96","author":"Cotin","year":"2012","journal-title":"Antivir. Res."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e13689","DOI":"10.1111\/ctr.13689","article-title":"Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: a natural experiment","volume":"33","author":"Cristelli","year":"2019","journal-title":"Clin. Transpl."},{"key":"ref63","first-page":"404","article-title":"Is there a rationale to using leflunomide in early rheumatoid arthritis?","volume":"23","author":"Dayer","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.biotechadv.2015.12.014","article-title":"Quercetin and the mitochondria: a mechanistic view","volume":"34","author":"De Oliveira","year":"2016","journal-title":"Biotechnol. Adv."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejmech.2017.03.004","article-title":"Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders","volume":"131","author":"Dinda","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev. Med. Virol."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00705-011-0917-z","article-title":"Effects of baicalein on Sendai virus in vivo are linked to serum baicalin and its inhibition of hemagglutinin-neuraminidase","volume":"156","author":"Dou","year":"2011","journal-title":"Arch. Virol."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J. Clin. Virol."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3851\/IMP3028","article-title":"Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus","volume":"21","author":"Drouot","year":"2016","journal-title":"Antivir. Ther."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00109-001-0300-8","article-title":"Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses","volume":"80","author":"Efferth","year":"2002","journal-title":"J. Mol. Med."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1086\/591195","article-title":"The antiviral activities of artemisinin and Artesunate","volume":"47","author":"Efferth","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2016.08.027","article-title":"Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: a case series","volume":"135","author":"El Chaer","year":"2016","journal-title":"Antivir. Res."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/14787210.2021.1846521","article-title":"Hyperimmunoglobulin therapy for the prevention and treatment of congenital cytomegalovirus: a systematic review and meta-analysis","volume":"19","author":"El-Qushayri","year":"2021","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.antiviral.2005.08.002","article-title":"Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action","volume":"68","author":"Evers","year":"2005","journal-title":"Antivir. Res."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0166-3542(02)00094-3","article-title":"Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus","volume":"56","author":"Evers","year":"2002","journal-title":"Antivir. Res."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"e0232140","DOI":"10.1371\/journal.pone.0232140","article-title":"Placental transfer of Letermovir and Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection","volume":"15","author":"Faure Bardon","year":"2020","journal-title":"PLoS One"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"342.e1","DOI":"10.1016\/j.ajog.2011.05.030","article-title":"Pregestational, periconceptional, and gestational primary maternal cytomegalovirus infection: prenatal diagnosis in 508 pregnancies","volume":"205","author":"Feldman","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref78","year":"2021"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e2019001","DOI":"10.4084\/MJHID.2019.001","article-title":"In vivo emergence of UL56 C325Y cytomegalovirus resistance to Letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation","volume":"11","author":"Frietsch","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.1002\/chem.201800729","article-title":"Synthesis of artemisinin-derived dimers, trimers and dendrimers: investigation of their antimalarial and antiviral activities including putative mechanisms of action","volume":"24","author":"Fr\u00f6hlich","year":"2018","journal-title":"Chemistry"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1592\/phco.30.10.1044","article-title":"Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology","volume":"30","author":"Gabardi","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00044-016-1607-x","article-title":"Anticancer properties of baicalein: a review","volume":"25","author":"Gao","year":"2016","journal-title":"Med. Chem. Res."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.antiviral.2018.11.005","article-title":"Targeting the terminase: an important step forward in the treatment and prophylaxis of human cytomegalovirus infections","volume":"161","author":"Gentry","year":"2019","journal-title":"Antivir. Res."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bcp.2010.09.005","article-title":"Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase","volume":"81","author":"Gentry","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1128\/AAC.00468-10","article-title":"Stereoselective phosphorylation of Cyclopropavir by pUL97 and competitive inhibition by Maribavir","volume":"54","author":"Gentry","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1128\/AAC.00214-13","article-title":"Resistance of human cytomegalovirus to Cyclopropavir maps to a base pair deletion in the open Reading frame of UL97","volume":"57","author":"Gentry","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"558","DOI":"10.12659\/AOT.898050","article-title":"Functional properties of human cytomegalovirus Hyperimmunoglobulin and standard immunoglobulin preparations","volume":"21","author":"Germer","year":"2016","journal-title":"Ann. Transplant."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.antiviral.2013.10.014","article-title":"Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus","volume":"101","author":"Germi","year":"2014","journal-title":"Antivir. Res."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.bbmt.2019.04.028","article-title":"Use of Leflunomide for treatment of cytomegalovirus infection in recipients of allogeneic stem cell transplant","volume":"25","author":"Gokarn","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel Anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral Terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"52","DOI":"10.7399\/fh.2016.40.1.10161","article-title":"Use of leflunomide in a cytomegalovirus infection resistant: a report of a case","volume":"40","author":"G\u00f3mez Valbuena","year":"2016","journal-title":"Farm Hosp."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0166-3542(94)90251-8","article-title":"The disposition in rats and monkeys of 2-bromo-5,6-dichloro-1-(\u03b2-D-ribofuranosyl)-benzimidazole (BDCRB) and its 4,5,6,-trichloro-cohner (TCRB)","volume":"23","author":"Good","year":"1994","journal-title":"Antivir. Res."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/biom9090482","article-title":"Quercetin interrupts the positive feedback loop between STAT3 and IL-6, promotes autophagy, and reduces ROS, preventing EBV-driven B cell immortalization","volume":"9","author":"Granato","year":"2019","journal-title":"Biomol. Ther."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.antiviral.2018.02.013","article-title":"Artesunate-derived monomeric, dimeric and trimeric experimental drugs \u2013 their unique mechanistic basis and pronounced antiherpesviral activity","volume":"152","author":"Hahn","year":"2018","journal-title":"Antivir. Res."},{"key":"ref95","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcv.2013.02.005","article-title":"First therapeutic use of Artesunate in treatment of human herpesvirus 6B myocarditis in a child","volume":"57","author":"Hakacova","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"e02405","DOI":"10.1128\/aac.02405-21","article-title":"New perspectives on antimicrobial agents: Maribavir","volume":"66","author":"Halpern-Cohen","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"e01627","DOI":"10.1128\/AAC.01627-20","article-title":"Investigational antiviral therapy models for the prevention and treatment of congenital cytomegalovirus infection during pregnancy","volume":"65","author":"Hamilton","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"e1000275","DOI":"10.1371\/journal.ppat.1000275","article-title":"Viral mimicry of Cdc2\/cyclin-dependent kinase 1 mediates disruption of nuclear Lamina during human cytomegalovirus nuclear egress","volume":"5","author":"Hamirally","year":"2009","journal-title":"PLoS Pathog."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.antiviral.2018.09.015","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses","volume":"159","author":"Hartline","year":"2018","journal-title":"Antivir. Res."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/TP.0b013e318276a1ef","article-title":"Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients","volume":"95","author":"Havenith","year":"2013","journal-title":"Transplantation"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C virus infection","volume":"67","author":"Hepatitis","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/01.tp.0000290686.68910.bd","article-title":"A lower incidence of cytomegalovirus infection in De novo heart transplant recipients randomized to Everolimus","volume":"84","author":"Hill","year":"2007","journal-title":"Transplantation"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1172\/JCI11918","article-title":"Hostile takeovers: viral appropriation of the NF-kB pathway","volume":"107","author":"Hiscott","year":"2001","journal-title":"J. Clin. Invest."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1913569","article-title":"A trial of Hyperimmune globulin to prevent congenital cytomegalovirus infection","volume":"385","author":"Hughes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/mnfr.201500144","article-title":"Quercetin is a potent anti-atherosclerotic compound by activation of SIRT1 signaling under oxLDL stimulation","volume":"59","author":"Hung","year":"2015","journal-title":"Mol. Nutr. Food Res."},{"key":"ref106","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.antiviral.2015.10.003","article-title":"The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-\u03baB) pathway by targeting RelA\/p65","volume":"124","author":"Hutterer","year":"2015","journal-title":"Antivir. Res."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/rmv.659","article-title":"Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV","volume":"20","author":"Hyde","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref108","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1536\/ihj.53.199","article-title":"Successful conversion to Everolimus after cytomegalovirus infection in a heart transplant recipient","volume":"53","author":"Imamura","year":"2012","journal-title":"Int. Heart J."},{"key":"ref109","doi-asserted-by":"publisher","first-page":"104700","DOI":"10.1016\/j.antiviral.2019.104700","article-title":"A highly potent trimeric derivative of artesunate shows promising treatment profiles in experimental models for congenital HCMV infection in vitro and ex vivo","volume":"175","author":"Jacquet","year":"2020","journal-title":"Antivir. Res."},{"key":"ref110","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1128\/AAC.00571-11","article-title":"Cyclopropavir inhibits the Normal function of the human cytomegalovirus UL97 kinase\u25bf","volume":"55","author":"James","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref111","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1128\/AAC.00062-13","article-title":"Selection and recombinant phenotyping of a novel CMX001 and Cidofovir resistance mutation in human cytomegalovirus","volume":"57","author":"James","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref112","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1016\/j.transproceed.2005.10.116","article-title":"A prospective evaluation of Leflunomide therapy for cytomegalovirus disease in renal transplant recipients","volume":"37","author":"John","year":"2005","journal-title":"Transplant. Proc."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/uog.23596","article-title":"Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study","volume":"57","author":"Kagan","year":"2021","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref114","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/uog.19164","article-title":"Prevention of maternal\u2013fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration","volume":"53","author":"Kagan","year":"2019","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1080\/22221751.2022.2095933","article-title":"Mysterious cases of acute hepatitis in children: is adenovirus still a lead suspect? Emerg","volume":"11","author":"Kajon","year":"2022","journal-title":"Microbes Infect."},{"key":"ref116","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.chom.2011.02.001","article-title":"HATs On for drug resistance","volume":"9","author":"Kamil","year":"2011","journal-title":"Cell Host Microbe"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/ajt.16946","article-title":"Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: a randomized, open-label, multicenter phase 4 trial","volume":"22","author":"Kaminski","year":"","journal-title":"Am. J. Transplant."},{"key":"ref118","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1681\/ASN.2020121753","article-title":"mTOR inhibitors prevent CMV infection through the restoration of functional \u03b1\u03b2 and \u03b3\u03b4 T cells in kidney transplantation","volume":"33","author":"Kaminski","year":"","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref119","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.antiviral.2005.10.003","article-title":"The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo","volume":"69","author":"Kaptein","year":"2006","journal-title":"Antivir. Res."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1039\/C4FO01178C","article-title":"Quercetin and related polyphenols: new insights and implications for their bioactivity and bioavailability","volume":"6","author":"Kawabata","year":"2015","journal-title":"Food Funct."},{"key":"ref122","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev. Med. Virol."},{"key":"ref123","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1128\/AAC.48.12.4745-4753.2004","article-title":"Oral activity of a methylenecyclopropane analog, Cyclopropavir, in animal models for cytomegalovirus infections","volume":"48","author":"Kern","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref124","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1128\/AAC.48.9.3516-3522.2004","article-title":"Oral treatment of murine cytomegalovirus infections with ether lipid esters of Cidofovir","volume":"48","author":"Kern","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref125","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1128\/AAC.48.5.1749-1755.2004","article-title":"Activities of Benzimidazole d- and l-Ribonucleosides in animal models of cytomegalovirus infections","volume":"48","author":"Kern","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref126","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1128\/AAC.49.3.1039-1045.2005","article-title":"In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication","volume":"49","author":"Kern","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref127","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3390\/molecules25102379","article-title":"Antiviral activities of quercetin and Isoquercitrin against human herpesviruses","volume":"25","author":"Kim","year":"2020","journal-title":"Molecules"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref129","doi-asserted-by":"publisher","first-page":"105362","DOI":"10.1016\/j.antiviral.2022.105362","article-title":"Poloxamer 188 \u2013 quercetin formulations amplify in vitro ganciclovir antiviral activity against cytomegalovirus","volume":"204","author":"Kjar","year":"2022","journal-title":"Antivir. Res."},{"key":"ref130","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00007890-200101150-00031","article-title":"Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide","volume":"71","author":"Knight","year":"2001","journal-title":"Transplantation"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/tid.12007","article-title":"Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation","volume":"15","author":"Kobashigawa","year":"2013","journal-title":"Transpl. Infect. Dis."},{"key":"ref132","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1128\/JVI.78.2.710-715.2004","article-title":"Role of a mutation in human cytomegalovirus gene UL104 in resistance to Benzimidazole Ribonucleosides","volume":"78","author":"Komazin","year":"2004","journal-title":"J. Virol."},{"key":"ref133","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1128\/AAC.01726-13","article-title":"Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions","volume":"58","author":"Komazin-Meredith","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref134","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","article-title":"Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication","volume":"46","author":"Koszalka","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref135","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the Management of Cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1128\/AAC.46.2.478-486.2002","article-title":"Phosphorylation of \u03b2-d-Ribosylbenzimidazoles is not required for activity against human cytomegalovirus","volume":"46","author":"Krosky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref137","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/095632020001100506","article-title":"Differences in DNA packaging genes and sensitivity to Benzimidazole Ribonucleosides between human cytomegalovirus strains AD169 and Towne","volume":"11","author":"Krosky","year":"2000","journal-title":"Antivir. Chem. Chemother."},{"key":"ref138","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/JVI.72.6.4721-4728.1998","article-title":"Resistance of human cytomegalovirus to Benzimidazole Ribonucleosides maps to two open Reading frames: UL89 and UL56","volume":"72","author":"Krosky","year":"1998","journal-title":"J. Virol."},{"key":"ref139","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1211\/002235702522","article-title":"Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats","volume":"55","author":"Lai","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"ref140","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/infdis\/jiw073","article-title":"Analysis of mutations in the gene encoding cytomegalovirus DNA polymerase in a phase 2 clinical trial of Brincidofovir prophylaxis","volume":"214","author":"Lanier","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref141","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12272-017-0898-x","article-title":"The anti-HSV-1 effect of quercetin is dependent on the suppression of TLR-3 in raw 264.7 cells","volume":"40","author":"Lee","year":"2017","journal-title":"Arch. Pharm. Res."},{"key":"ref142","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ajog.2020.02.018","article-title":"Cytomegalovirus infection during pregnancy: state of the science","volume":"223","author":"Leruez-Ville","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref143","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/pd.5757","article-title":"Is it time for routine prenatal serological screening for congenital cytomegalovirus?","volume":"40","author":"Leruez-Ville","year":"2020","journal-title":"Prenat. Diagn."},{"key":"ref144","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1111\/cts.13063","article-title":"Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: a single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study","volume":"14","author":"Li","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref145","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3892\/or.2016.5108","article-title":"Baicalein inhibits TNF-\u03b1-induced NF-\u03baB activation and expression of NF-\u03baB-regulated target gene products","volume":"36","author":"Li","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref146","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4269\/ajtmh.2002.66.516","article-title":"Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents","volume":"66","author":"Li","year":"2002","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref147","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jep.2014.08.031","article-title":"Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects","volume":"156","author":"Li","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"ref148","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: a close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"ref149","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs Valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"e13687","DOI":"10.1111\/tid.13687","article-title":"Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref151","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel Anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref152","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.antiviral.2016.06.008","article-title":"Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir","volume":"132","author":"Lischka","year":"2016","journal-title":"Antivir. Res."},{"key":"ref153","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/358160a0","article-title":"Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir","volume":"358","author":"Littler","year":"1992","journal-title":"Nature"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref155","first-page":"898","article-title":"Maribavir (ViroPharma)","volume":"5","author":"Lu","year":"2000","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.apsb.2020.06.008","article-title":"Inhibitory effects of baicalein against herpes simplex virus type 1","volume":"10","author":"Luo","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref158","doi-asserted-by":"publisher","first-page":"e02467","DOI":"10.1128\/AAC.02467-19","article-title":"Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation","volume":"64","author":"Maertens","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref159","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0338-4535(84)80178-6","article-title":"Preparation of a specific anti-cytomegalovirus immunoglobulin for intravenous injection","volume":"27","author":"Maniez-Montreuil","year":"1984","journal-title":"Rev. Fr. Transfus. Immunohematol."},{"key":"ref160","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel Anticytomegalovirus compound AIC246 (Letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref161","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref162","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of Oral Brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref163","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref164","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1365-2125.2011.04103.x","article-title":"Artesunate\/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects","volume":"73","author":"McGready","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref165","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1128\/AAC.45.10.2925-2927.2001","article-title":"Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir","volume":"45","author":"McSharry","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref166","doi-asserted-by":"publisher","first-page":"11115","DOI":"10.1128\/JVI.79.17.11115-11127.2005","article-title":"Impact of 2-Bromo-5,6-Dichloro-1-\u03b2-d-Ribofuranosyl Benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation","volume":"79","author":"McVoy","year":"2005","journal-title":"J. Virol."},{"key":"ref167","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4615-5335-9_13","article-title":"Effect of plant flavonoids on immune and inflammatory cell function","volume":"439","author":"Middleton","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref168","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/vox.12246","article-title":"In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins","volume":"109","author":"Miescher","year":"2015","journal-title":"Vox Sang."},{"key":"ref169","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1021\/jm970545c","article-title":"Design, synthesis, and antiviral activity of \u03b1-nucleosides: d- and l-isomers of Lyxofuranosyl- and (5-Deoxylyxofuranosyl)benzimidazoles","volume":"41","author":"Migawa","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref170","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jcv.2009.05.017","article-title":"Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate","volume":"46","author":"Milbradt","year":"2009","journal-title":"J. Clin. Virol."},{"key":"ref171","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/bdd.605","article-title":"Quercetin pharmacokinetics in humans","volume":"29","author":"Moon","year":"2008","journal-title":"Biopharm. Drug Dispos."},{"key":"ref172","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.placenta.2014.11.003","article-title":"Ex vivo model of congenital cytomegalovirus infection and new combination therapies","volume":"36","author":"Mor\u00e8re","year":"2015","journal-title":"Placenta"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0006-2952(02)00842-0","article-title":"Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events","volume":"63","author":"Mukherjee","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref174","doi-asserted-by":"publisher","first-page":"105361","DOI":"10.1016\/j.antiviral.2022.105361","article-title":"First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure","volume":"204","author":"Muller","year":"2022","journal-title":"Antivir. Res."},{"key":"ref175","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1248\/yakushi1947.118.3_79","article-title":"The chemical structure of new substance as the metabolite of baicalin and time profiles for the plasma concentration after oral administration of sho-saiko-to in human","volume":"118","author":"Muto","year":"1998","journal-title":"Yakugaku Zasshi"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0031-9422(99)00593-2","article-title":"Purification and characterization of UDP-glucuronate: baicalein 7-O-glucuronosyltransferase from Scutellaria baicalensis Georgi. Cell suspension cultures","volume":"53","author":"Nagashima","year":"2000","journal-title":"Phytochemistry"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.oooo.2014.12.002","article-title":"Clinical implications of prescribing nonsteroidal anti-inflammatory drugs in oral health care\u2014a review","volume":"119","author":"Nagi","year":"2015","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref178","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3390\/nu7042345","article-title":"Estimated Daily intake and seasonal food sources of quercetin in Japan","volume":"7","author":"Nishimuro","year":"2015","journal-title":"Nutrients"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1128\/JVI.78.4.1623-1635.2004","article-title":"Dramatic effects of 2-Bromo-5,6-Dichloro-1-\u03b2-d-Ribofuranosyl Benzimidazole riboside on the genome structure, packaging, and egress of Guinea pig cytomegalovirus","volume":"78","author":"Nixon","year":"2004","journal-title":"J. Virol."},{"key":"ref180","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","article-title":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","volume":"158","author":"O\u2019Brien","year":"2018","journal-title":"Antivir. Res."},{"key":"ref181","doi-asserted-by":"publisher","first-page":"104639","DOI":"10.1016\/j.antiviral.2019.104639","article-title":"Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus","volume":"172","author":"Oiknine-Djian","year":"2019","journal-title":"Antivir. Res."},{"key":"ref182","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.reprotox.2005.02.002","article-title":"Fetal effects of primary and secondary cytomegalovirus infection in pregnancy","volume":"21","author":"Ornoy","year":"2006","journal-title":"Reprod. Toxicol."},{"key":"ref183","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.antiviral.2018.04.006","article-title":"A Guinea pig cytomegalovirus resistant to the DNA maturation inhibitor BDCRB","volume":"154","author":"Ourahmane","year":"2018","journal-title":"Antivir. Res."},{"key":"ref184","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-Spectrum Oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref185","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref186","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2147\/DDDT.S112852","article-title":"Clinical study in genital herpes: natural Gene-Eden-VIR\/Novirin versus acyclovir, valacyclovir, and famciclovir","volume":"10","author":"Polansky","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref187","doi-asserted-by":"publisher","first-page":"2515690X1880626","DOI":"10.1177\/2515690X18806269","article-title":"Clinical trial of herbal treatment Gene-Eden-VIR\/Novirin in Oral herpes","volume":"23","author":"Polansky","year":"2018","journal-title":"J. Evid. Based Integr. Med."},{"key":"ref188","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"ref189","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1128\/AAC.01523-10","article-title":"Benzimidazole Analogs Inhibit Human Herpesvirus 6\u25bf","volume":"55","author":"Prichard","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref190","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.mayocp.2018.09.017","article-title":"Application of a new paradigm for cytomegalovirus disease prevention in Mayo Clinic\u2019s first face transplant","volume":"94","author":"Razonable","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref191","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/jac\/48.6.757","article-title":"Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action","volume":"48","author":"Reefschlaeger","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref192","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1016\/j.bmc.2015.07.048","article-title":"Highly potent artemisinin-derived dimers and trimers: synthesis and evaluation of their antimalarial, antileukemia and antiviral activities","volume":"23","author":"Reiter","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref193","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.chom.2011.01.006","article-title":"Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest","volume":"9","author":"Reitsma","year":"2011","journal-title":"Cell Host Microbe"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref195","author":"Reza Nassiri","year":"1996"},{"key":"ref196","first-page":"50","article-title":"Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials","volume":"58","author":"Ribeiro","year":"1998","journal-title":"Med. Trop."},{"key":"ref197","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/09273948.2015.1071406","article-title":"Utility of Leflunomide in the treatment of drug resistant cytomegalovirus retinitis","volume":"25","author":"Rifkin","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref198","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2014.10.016","article-title":"Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection","volume":"113","author":"Ritt\u00e0","year":"2015","journal-title":"Antivir. Res."},{"key":"ref199","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref200","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jpeds.2005.09.003","article-title":"Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity","volume":"148","author":"Ross","year":"2006","journal-title":"J. Pediatr."},{"key":"ref201","doi-asserted-by":"publisher","first-page":"e00717","DOI":"10.1128\/AAC.00717-19","article-title":"Phase Ib trial to evaluate the safety and pharmacokinetics of multiple ascending doses of Filociclovir (MBX-400, Cyclopropavir) in healthy volunteers","volume":"63","author":"Rouphael","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref202","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jtm\/taw093","article-title":"Artesunate to treat severe malaria in travellers: review of efficacy and safety and practical implications","volume":"24","author":"Roussel","year":"2017","journal-title":"J. Travel Med."},{"key":"ref203","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.drudis.2022.02.013","article-title":"Nucleosides and emerging viruses: a new story","volume":"27","author":"Roy","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/ajt.12725","article-title":"New cell-signaling pathways for controlling cytomegalovirus replication","volume":"14","author":"Roy","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref205","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society\u2013USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"ref206","doi-asserted-by":"publisher","first-page":"e13655","DOI":"10.1111\/ctr.13655","article-title":"The use of CMVIg rescue therapy in cardiothoracic transplantation: a single-center experience over 6 years (2011-2017)","volume":"33","author":"Santhanakrishnan","year":"2019","journal-title":"Clin. Transpl."},{"key":"ref207","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcv.2017.03.005","article-title":"Comparison of cytomegalovirus (CMV)-specific neutralization capacity of hyperimmunoglobulin (HIG) versus standard intravenous immunoglobulin (IVIG) preparations: impact of CMV IgG normalization","volume":"90","author":"Schampera","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref208","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jcv.2007.10.008","article-title":"Comparison of vaccine strategies against congenital CMV infection in the guinea pig model","volume":"41","author":"Schleiss","year":"2008","journal-title":"J. Clin. Virol."},{"key":"ref209","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.antiviral.2004.09.004","article-title":"The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs","volume":"65","author":"Schleiss","year":"2005","journal-title":"Antivir. Res."},{"key":"ref210","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/nar\/gkg229","article-title":"Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus","volume":"31","author":"Scholz","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref211","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00404-020-05728-7","article-title":"Fetal and maternal outcome after hyperimmunoglobulin administration for prevention of maternal\u2013fetal transmission of cytomegalovirus during pregnancy: retrospective cohort analysis","volume":"302","author":"Seidel","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref212","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","article-title":"Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Shahar-Nissan","year":"2020","journal-title":"Lancet"},{"key":"ref213","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1086\/587106","article-title":"Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"46","author":"Shapira","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref214","doi-asserted-by":"publisher","first-page":"e13176","DOI":"10.1111\/ctr.13176","article-title":"Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: a case series and review of the literature","volume":"32","author":"Silva","year":"2018","journal-title":"Clin. Transpl."},{"key":"ref215","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jcph.2155","article-title":"Maribavir pharmacokinetics and safety in participants with moderate hepatic impairment: a phase 1, open-label, single-dose, parallel group study","volume":"63","author":"Song","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"ref216","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2018.11.008","article-title":"In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model","volume":"161","author":"Sonntag","year":"2019","journal-title":"Antivir. Res."},{"key":"ref217","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1161\/01.RES.83.2.210","article-title":"Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by Cyclooxygenase-2 in coronary artery smooth muscle cells","volume":"83","author":"Speir","year":"1998","journal-title":"Circ. Res."},{"key":"ref218","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl. Int."},{"key":"ref219","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/0091270006296765","article-title":"Pharmacokinetics of Maribavir, a novel Oral Anticytomegalovirus agent, in subjects with varying degrees of renal impairment","volume":"47","author":"Swan","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref220","doi-asserted-by":"publisher","first-page":"e13679","DOI":"10.1111\/ctr.13679","article-title":"Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients","volume":"33","author":"Taber","year":"2019","journal-title":"Clin. Transpl."},{"key":"ref221","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/jps.20593","article-title":"Investigation of the absorption mechanisms of baicalin and baicalein in rats","volume":"95","author":"Taiming","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"ref222","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of Everolimus with reduced Calcineurin inhibitor exposure in De novo kidney transplants: an analysis from the randomized TRANSFORM study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"ref223","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.fitote.2011.12.019","article-title":"Pharmacokinetic study of baicalein after oral administration in monkeys","volume":"83","author":"Tian","year":"2012","journal-title":"Fitoterapia"},{"key":"ref224","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/FTD.0000000000000353","article-title":"Brincidofovir is not a substrate for the human organic anion transporter 1: a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies","volume":"38","author":"Tippin","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref225","doi-asserted-by":"publisher","first-page":"105431","DOI":"10.1016\/j.antiviral.2022.105431","article-title":"Filociclovir is a potent inhibitor of human adenovirus F41","volume":"208","author":"Tollefson","year":"2022","journal-title":"Antivir. Res."},{"key":"ref226","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.toxlet.2006.06.001","article-title":"Are currently deployed artemisinins neurotoxic?","volume":"166","author":"Toovey","year":"2006","journal-title":"Toxicol. Lett."},{"key":"ref227","doi-asserted-by":"publisher","first-page":"e01299","DOI":"10.1128\/AAC.01299-20","article-title":"Filociclovir is a potent in vitro and in vivo inhibitor of human adenoviruses","volume":"64","author":"Toth","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref228","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1021\/jm00020a025","article-title":"Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles","volume":"38","author":"Townsend","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref229","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/nu2121231","article-title":"Chemistry and biochemistry of dietary polyphenols","volume":"2","author":"Tsao","year":"2010","journal-title":"Nutrients"},{"key":"ref230","doi-asserted-by":"publisher","first-page":"118183","DOI":"10.1016\/j.lfs.2020.118183","article-title":"Baicalein: a metabolite with promising antineoplastic activity","volume":"259","author":"Tuli","year":"2020","journal-title":"Life Sci."},{"key":"ref231","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1128\/JVI.72.1.717-725.1998","article-title":"Inhibition of human cytomegalovirus DNA maturation by a Benzimidazole Ribonucleoside is mediated through the UL89 gene product","volume":"72","author":"Underwood","year":"1998","journal-title":"J. Virol."},{"key":"ref232","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/TP.0000000000002886","article-title":"Letermovir for difficult to treat cytomegalovirus infection in lung transplant recipients","volume":"104","author":"Veit","year":"2020","journal-title":"Transplantation"},{"key":"ref233","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/3624146","article-title":"Brincidofovir use after Foscarnet crystal nephropathy in a kidney transplant recipient with multiresistant cytomegalovirus infection","volume":"2017","author":"Vial","year":"2017","journal-title":"Case Rep. Transplant."},{"key":"ref234","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/cid\/cis423","article-title":"Early primary cytomegalovirus infection in pregnancy: maternal Hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age","volume":"55","author":"Visentin","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref235","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000053979","article-title":"Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent Leflunomide","volume":"42","author":"Waldman","year":"","journal-title":"Intervirology"},{"key":"ref236","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/00007890-199909270-00014","article-title":"Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide","volume":"68","author":"Waldman","year":"","journal-title":"Transplantation"},{"key":"ref237","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","article-title":"Phase I safety and pharmacokinetic trials of 1263W94, a novel Oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects","volume":"47","author":"Wang","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref238","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0166-3542(01)00127-9","article-title":"Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo","volume":"49","author":"Weber","year":"2001","journal-title":"Antivir. Res."},{"key":"ref239","doi-asserted-by":"publisher","first-page":"104788","DOI":"10.1016\/j.antiviral.2020.104788","article-title":"The trimeric artesunate derivative TF27 exerts strong anti-cytomegaloviral efficacy: focus on prophylactic efficacy and oral treatment of immunocompetent mice","volume":"178","author":"Wild","year":"2020","journal-title":"Antivir. Res."},{"key":"ref240","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref241","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of Benzimidazole d- and l-Ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref242","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/00007890-200202150-00008","article-title":"Experiences with LEFLUNOMIDE in solid organ transplantation","volume":"73","author":"Williams","year":"2002","journal-title":"Transplantation"},{"key":"ref243","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of Cidofovir and cyclic Cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref244","first-page":"3088","article-title":"Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide","volume":"28","author":"Williamson","year":"1996","journal-title":"Transplant. Proc."},{"key":"ref245","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"ref246","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.antiviral.2011.03.184","article-title":"Human cytomegalovirus kinetics following institution of Artesunate after hematopoietic stem cell transplantation","volume":"90","author":"Wolf","year":"2011","journal-title":"Antivir. Res."},{"key":"ref247","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3851\/IMP782","article-title":"L-valine Ester of Cyclopropavir - a new antiviral prodrug","volume":"20","author":"Wu","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"ref248","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1745-7254.2007.00510.x","article-title":"In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik","volume":"28","author":"Wu","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"ref249","doi-asserted-by":"publisher","first-page":"12398","DOI":"10.1074\/jbc.270.21.12398","article-title":"Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, Leflunomide (\u2217)","volume":"270","author":"Xu","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref250","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0166-3542(98)00049-7","article-title":"Comparison of antiviral compounds against human herpesvirus 6 and 7","volume":"40","author":"Yoshida","year":"1998","journal-title":"Antivir. Res."},{"key":"ref251","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/BF02978831","article-title":"Effects of triterpenoids and flavonoids isolated from Alnus firma on HIV-1 viral enzymes","volume":"30","author":"Yu","year":"2007","journal-title":"Arch. Pharm. Res."},{"key":"ref252","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.bmc.2005.11.041","article-title":"Selective COX-2 inhibitors: a review of their structure-activity relationships","volume":"10","author":"Zarghi","year":"2011","journal-title":"Iran J. Pharm. Res."},{"key":"ref253","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s11095-005-5303-7","article-title":"Role of intestinal first-pass metabolism of baicalein in its absorption process","volume":"22","author":"Zhang","year":"2005","journal-title":"Pharm. Res."},{"key":"ref254","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jpba.2004.07.024","article-title":"High-performance liquid chromatographic method for simultaneous determination of baicalein and baicalein 7-glucuronide in rat plasma","volume":"36","author":"Zhang","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref255","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11095-006-9126-y","article-title":"Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-Pass metabolism of flavonoid Baicalein","volume":"24","author":"Zhang","year":"2007","journal-title":"Pharm. Res."},{"key":"ref256","first-page":"342","article-title":"Pharmacokinetics of dihydroqinghaosu in human volunteers and comparison with qinghaosu","volume":"28","author":"Zhao","year":"1993","journal-title":"Yao Xue Xue Bao"},{"key":"ref257","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1021\/jm030316s","article-title":"Synthesis and antiviral activity of (Z)- and (E)-2,2-[Bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides","volume":"47","author":"Zhou","year":"2004","journal-title":"J. Med. Chem."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1321116\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T23:25:11Z","timestamp":1700436311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1321116\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":257,"alternative-id":["10.3389\/fmicb.2023.1321116"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2023.1321116","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"article-number":"1321116"}}